Skip to main content

Articles

Page 4 of 65

  1. Authors: Jinpeng Du, Tian Lan, Haotian Liao, Xuping Feng, Xing Chen, Wenwei Liao, Guimin Hou, Lin Xu, Qingbo Feng, Kunlin Xie, Mingheng Liao, Xiangzheng Chen, Jiwei Huang, Kefei Yuan and Yong Zeng
    Citation: Molecular Cancer 2023 22:134

    The original article was published in Molecular Cancer 2022 21:18

  2. Prostate cancer (PCa) is a common and fatal type of cancer in men. Metastatic PCa (mPCa) is a major factor contributing to its lethality, although the mechanisms remain poorly understood. PTEN is one of the mo...

    Authors: Jan Pencik, Cecile Philippe, Michaela Schlederer, Emine Atas, Matteo Pecoraro, Sandra Grund-Gröschke, Wen (Jess) Li, Amanda Tracz, Isabel Heidegger, Sabine Lagger, Karolína Trachtová, Monika Oberhuber, Ellen Heitzer, Osman Aksoy, Heidi A. Neubauer, Bettina Wingelhofer…
    Citation: Molecular Cancer 2023 22:133
  3. Chimeric antigen receptor (CAR) -T cell therapy is an efficient therapeutic strategy for specific hematologic malignancies. However, positive outcomes of this novel therapy in treating solid tumors are curtail...

    Authors: Jian Chen, Tianchuan Zhu, Guanmin Jiang, Qi Zeng, Zhijian Li and Xi Huang
    Citation: Molecular Cancer 2023 22:131
  4. The reversible oxidation-reduction homeostasis mechanism functions as a specific signal transduction system, eliciting related physiological responses. Disruptions to redox homeostasis can have negative conseq...

    Authors: Yuqing Ren, Ruizhi Wang, Siyuan Weng, Hui Xu, Yuyuan Zhang, Shuang Chen, Shutong Liu, Yuhao Ba, Zhaokai Zhou, Peng Luo, Quan Cheng, Qin Dang, Zaoqu Liu and Xinwei Han
    Citation: Molecular Cancer 2023 22:130
  5. This Phase 1 study evaluates the intra- and peritumoral administration by convection enhanced delivery (CED) of human recombinant Bone Morphogenetic Protein 4 (hrBMP4) – an inhibitory regulator of cancer stem ...

    Authors: Eelke M. Bos, Elena Binda, Iris S.C. Verploegh, Eva Wembacher, Daphna Hoefnagel, Rutger K. Balvers, Anne L. Korporaal, Andrea Conidi, Esther A. H. Warnert, Nadia Trivieri, Alberto Visioli, Paola Zaccarini, Laura Caiola, Rogier van Wijck, Peter van der Spek, Danny Huylebroeck…
    Citation: Molecular Cancer 2023 22:129
  6. Protein regulator of cytokinesis 1 (PRC1) is involved in cytokinesis. Growing evidence suggests the association of PRC1 with multiple cancers. Here, we unveil that, in 28 cancer types, PRC1 is higher expressed...

    Authors: Sijing Li, Omar Motiño, Flavia Lambertucci, Isabelle Martins, Li Sun and Guido Kroemer
    Citation: Molecular Cancer 2023 22:128
  7. Approximately 15% of adult GIST patients harbor tumors that are wild-type for KIT and PDGFRα genes (KP-wtGIST). These tumors usually have SDH deficiencies, exhibit a more indolent behavior and are resistant to...

    Authors: Javier Martin-Broto, Claudia Valverde, Nadia Hindi, Bruno Vincenzi, Javier Martinez-Trufero, Giovanni Grignani, Antoine Italiano, Javier Lavernia, Ana Vallejo, Paolo Dei Tos, Francois Le Loarer, Ricardo Gonzalez-Campora, Rafael Ramos, Diana Hernández-Jover, Antonio Gutierrez, Cesar Serrano…
    Citation: Molecular Cancer 2023 22:127
  8. Children with birth defects (BD) express distinct clinical features that often have various medical consequences, one of which is predisposition to the development of cancers. Identification of the underlying ...

    Authors: Yichuan Liu, Hui-Qi Qu, Xiao Chang, Frank D Mentch, Haijun Qiu, Xiang Wang, Amir Hossein Saeidian, Deborah Watson, Joseph Glessner and Hakon Hakonarson
    Citation: Molecular Cancer 2023 22:126
  9. Hairy cell leukemia (HCL) is a B-lymphoma induced by BRAF(V600E) mutation. However, introducing BRAF(V600E) in B-lymphocytes fails to induce hematological malignancy, suggesting that BRAF(V600E) needs concurre...

    Authors: Jiajun Yap, Jimin Yuan, Wan Hwa Ng, Gao Bin Chen, Yuen Rong M. Sim, Kah Chun Goh, Joey Teo, Trixie Y. H. Lim, Shee Min Goay, Jia Hao Jackie Teo, Zhentang Lao, Paula Lam, Kanaga Sabapathy and Jiancheng Hu
    Citation: Molecular Cancer 2023 22:125
  10. Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study aimed to examine anlotinib plus icotinib as a first-...

    Authors: Linlin Zhang, Liuchun Wang, Jingya Wang, Jinliang Chen, Zhaoting Meng, Zhujun Liu, Xiangli Jiang, Xinyue Wang, Chun Huang, Peng Chen, Yan Liang, Richeng Jiang, Jing Wang, Diansheng Zhong, Yanhong Shang, Yan Zhang…
    Citation: Molecular Cancer 2023 22:124
  11. Lung cancer is the leading cause of cancer-related deaths worldwide. Long non-coding RNAs (lncRNAs) have emerged as key regulators of cancer development and progression, and as promising biomarkers for the dia...

    Authors: Qiurong Yang, Maoye Wang, Jing Xu, Dan Yu, Yixin Li, Yanke Chen, Xiaoxin Zhang, Jiahui Zhang, Jianmei Gu and Xu Zhang
    Citation: Molecular Cancer 2023 22:122
  12. Non-small cell lung cancer is a very poor prognosis disease. Molecular analyses have highlighted several genetic alterations which may be targeted by specific therapies. In clinical practice, progression-free ...

    Authors: Lorraine Dalens, Julie Niogret, Corentin Richard, Sandy Chevrier, Pascal Foucher, Bruno Coudert, Aurélie Lagrange, Laure Favier, Virginie Westeel, Stefano Kim, Olivier Adotevi, Caroline Chapusot, Laurent Martin, Laurent Arnould, Courèche-Guillaume Kaderbhai and Romain Boidot
    Citation: Molecular Cancer 2023 22:120
  13. Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome d...

    Authors: Raquel García-Vílchez, Ana M. Añazco-Guenkova, Sabine Dietmann, Judith López, Virginia Morón-Calvente, Silvia D’Ambrosi, Paz Nombela, Kepa Zamacola, Isabel Mendizabal, Saioa García-Longarte, Amaia Zabala-Letona, Ianire Astobiza, Sonia Fernández, Alejandro Paniagua, Borja Miguel-López, Virginie Marchand…
    Citation: Molecular Cancer 2023 22:119
  14. The encapsulation of circular RNAs (circRNAs) into extracellular vesicles (EVs) enables their involvement in intercellular communication and exerts an influence on the malignant advancement of various tumors. ...

    Authors: Tao He, Qiansheng Zhang, Peng Xu, Wen Tao, Fuyang Lin, Renfei Liu, Mingzhao Li, Xiaolu Duan, Chao Cai, Di Gu, Guohua Zeng and Yongda Liu
    Citation: Molecular Cancer 2023 22:117
  15. Malignant Pleural Mesothelioma (MPM) is a dreadful disease escaping the classical genetic model of cancer evolution and characterized by wide heterogeneity and transcriptional plasticity. Clinical evolution of...

    Authors: F Torricelli, B Donati, F Reggiani, V Manicardi, S Piana, R Valli, F Lococo and Alessia Ciarrocchi
    Citation: Molecular Cancer 2023 22:114
  16. Osteosarcoma (OS) is the most prevalent orthopedic malignancy with a dismal prognosis. The high iron absorption rate in OS cells of patients suggests that ferroptosis may be related to the progression of OS, b...

    Authors: Mingyang Jiang, Yiji Jike, Kaicheng Liu, Fu Gan, Ke Zhang, Mingjing Xie, Junlei Zhang, Chuanliang Chen, Xiaochong Zou, Xiaohong Jiang, Yongheng Dai, Weikui Chen, Yue Qiu and Zhandong Bo
    Citation: Molecular Cancer 2023 22:113
  17. The mechanistic/mammalian target of rapamycin (mTOR), a protein discovered in 1991, integrates a complex pathway with a key role in maintaining cellular homeostasis. By comprising two functionally distinct com...

    Authors: A Marques-Ramos and R Cervantes
    Citation: Molecular Cancer 2023 22:112
  18. The diagnosis of brain metastasis (BrM) has historically been a dooming diagnosis that is nothing less than a death sentence, with few treatment options for palliation or prolonging life. Among the few treatme...

    Authors: Aatiya Ahmad, Parvez Khan, Asad Ur Rehman, Surinder Kumar Batra and Mohd Wasim Nasser
    Citation: Molecular Cancer 2023 22:111
  19. Drugs targeting the spindle assembly checkpoint (SAC), such as inhibitors of Aurora kinase B (AURKB) and dual specific protein kinase TTK, are in different stages of clinical development. However, cell respons...

    Authors: Jordi Bertran-Alamillo, Ana Giménez-Capitán, Ruth Román, Sara Talbot, Rebecca Whiteley, Nicolas Floc’h, Elizabeth Martínez-Pérez, Matthew J. Martin, Paul D. Smith, Ivana Sullivan, Mikkel G. Terp, Jamal Saeh, Cristina Marino-Buslje, Giulia Fabbri, Grace Guo, Man Xu…
    Citation: Molecular Cancer 2023 22:110
  20. Authors: Yongyan Wu, Yuliang Zhang, Xiwang Zheng, Fengsheng Dai, Yan Lu, Li Dai, Min Niu, Huina Guo, Wenqi Li, Xuting Xue, Yunfeng Bo, Yujia Guo, Jiangbo Qin, Yixiao Qin, Hongliang Liu, Yu Zhang…
    Citation: Molecular Cancer 2023 22:109

    The original article was published in Molecular Cancer 2020 19:99

  21. The reintegration of excised signal joints resulting from human V(D)J recombination was described as a potent source of genomic instability in human lymphoid cancers. However, such molecular events have not be...

    Authors: Estelle Balducci, Thomas Steimlé, Charlotte Smith, Patrick Villarese, Mélanie Feroul, Dominique Payet-Bornet, Sophie Kaltenbach, Lucile Couronné, Ludovic Lhermitte, Aurore Touzart, Marie-Emilie Dourthe, Mathieu Simonin, André Baruchel, Hervé Dombret, Norbert Ifrah, Nicolas Boissel…
    Citation: Molecular Cancer 2023 22:108
  22. Acute leukemias represent deadly malignancies that require better treatment. As a challenge, treatment is counteracted by a microenvironment protecting dormant leukemia stem cells.

    Authors: Ehsan Bahrami, Jan Philipp Schmid, Vindi Jurinovic, Martin Becker, Anna-Katharina Wirth, Romina Ludwig, Sophie Kreissig, Tania Vanessa Duque Angel, Diana Amend, Katharina Hunt, Rupert Öllinger, Roland Rad, Joris Maximilian Frenz, Maria Solovey, Frank Ziemann, Matthias Mann…
    Citation: Molecular Cancer 2023 22:107
  23. Breast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presents a big challenge in its therapeutic management. However, recent advances in molecular biology a...

    Authors: Feng Ye, Saikat Dewanjee, Yuehua Li, Niraj Kumar Jha, Zhe-Sheng Chen, Ankush Kumar, Vishakha, Tapan Behl, Saurabh Kumar Jha and Hailin Tang
    Citation: Molecular Cancer 2023 22:105
  24. The treatment of Triple-negative breast cancer (TNBC) has always been challenging due to its heterogeneity and the absence of well-defined molecular targets. The present study aims to elucidate the role of pro...

    Authors: Runjie Song, Peilan Guo, Xin Ren, Lijun Zhou, Peng Li, Nafis A Rahman, Sławomir Wołczyński, Xiru Li, Yanjun Zhang, Mei Liu, Jiali Liu and Xiangdong Li
    Citation: Molecular Cancer 2023 22:104
  25. Tyrosine kinase inhibitors (TKIs) that specifically target mutational points in the EGFR gene have significantly reduced suffering and provided greater relief to patients with lung adenocarcinoma (LUAD). The t...

    Authors: Kai Li, Zi-Yang Peng, Rui Wang, Xiang Li, Ning Du, Da-Peng Liu, Jia Zhang, Yun-Feng Zhang, Lei Ma, Ye Sun, Shou-Ching Tang, Hong Ren, Yi-Ping Yang and Xin Sun
    Citation: Molecular Cancer 2023 22:103
  26. Divergent N6-methyladenosine (m6A) modifications are dynamic and reversible posttranscriptional RNA modifications that are mediated by m6A regulators or m6A RNA methylation regulators, i.e., methyltransferases (“...

    Authors: Yumin Wang, Yan Wang, Harsh Patel, Jichao Chen, Jinhua Wang, Zhe-Sheng Chen and Hongquan Wang
    Citation: Molecular Cancer 2023 22:102
  27. Chimeric Antigen Receptor (CAR) T cells are now standard of care (SOC) for some patients with B cell and plasma cell malignancies and could disrupt the therapeutic landscape of solid tumors. However, access to...

    Authors: Hyatt Balke-Want, Vimal Keerthi, Nikolaos Gkitsas, Andrew G. Mancini, Gavin L. Kurgan, Carley Fowler, Peng Xu, Xikun Liu, Kyle Asano, Sunny Patel, Christopher J. Fisher, Annie K. Brown, Ramya H. Tunuguntla, Shabnum Patel, Elena Sotillo, Crystal L. Mackall…
    Citation: Molecular Cancer 2023 22:100
  28. Lung adenocarcinoma (LUAD) is a common type of lung cancer with a high risk of metastasis, but the exact molecular mechanisms of metastasis are not yet understood.

    Authors: Han Fang, Qi Sun, Jin Zhou, Huijuan Zhang, Qiong Song, Hua Zhang, Guohua Yu, Ying Guo, Chengyu Huang, Yakui Mou, Chuanliang Jia, Yingjian Song, Aina Liu, Kaiyu Song, Congxian Lu, Ruxian Tian…
    Citation: Molecular Cancer 2023 22:99
  29. Cancer is a grievous disease whose treatment requires a more efficient, non-invasive therapy, associated with minimal side effects. Gold nanoparticles possessing greatly impressive optical properties have been...

    Authors: Prashant Kesharwani, Ruiyang Ma, Liang Sang, Mahak Fatima, Afsana Sheikh, Mohammed A. S. Abourehab, Neelima Gupta, Zhe-Sheng Chen and Yun Zhou
    Citation: Molecular Cancer 2023 22:98
  30. Authors: Rodrigo Entrialgo‑Cadierno, Cristina Cueto‑Ureña, Connor Welch, Iker Feliu, Irati Macaya, Laura Vera, Xabier Morales, Sandra Vietti Michelina, Pietro Scaparone, Ines Lopez, Elodie Darbo, Oihane Erice, Adrian Vallejo, Haritz Moreno, Ainhoa Goñi‑Salaverri, David Lara‑Astiaso…
    Citation: Molecular Cancer 2023 22:97

    The original article was published in Molecular Cancer 2023 22:86

  31. Cancer is the most prevalent cause of death globally, and radiotherapy is considered the standard of care for most solid tumors, including lung, breast, esophageal, and colorectal cancers and glioblastoma. Res...

    Authors: Yu Wu, Yingqiu Song, Runze Wang and Tianlu Wang
    Citation: Molecular Cancer 2023 22:96
  32. Clinical hyperthermic intraperitoneal chemotherapy (HIPEC) is regarded as a potential treatment that can prolong survival of patients with peritoneal metastases after cytoreductive surgery. However, treated tu...

    Authors: Qiang Wang, Peng Liu, Yingfei Wen, Kuan Li, Bo Bi, Bin-bin Li, Miaojuan Qiu, Shiqiang Zhang, You Li, Jia Li, Hengxing Chen, Yuan Yin, Leli Zeng, Changhua Zhang, Yulong He and Jing Zhao
    Citation: Molecular Cancer 2023 22:95
  33. Over the past decade, immune checkpoint inhibitors (ICIs) have emerged as a revolutionary cancer treatment modality, offering long-lasting responses and survival benefits for a substantial number of cancer pat...

    Authors: Xianjing Chu, Wentao Tian, Ziqi Wang, Jing Zhang and Rongrong Zhou
    Citation: Molecular Cancer 2023 22:93

    The Correction to this article has been published in Molecular Cancer 2023 22:101

  34. Though the CXCR2 chemokine receptor is known to play a key role in cancer growth and response to therapy, a direct link between expression of CXCR2 in tumor progenitor cells during induction of tumorigenesis h...

    Authors: J. Yang, K. Bergdorf, C. Yan, W. Luo, S. C. Chen, G.D. Ayers, Q. Liu, X. Liu, M. Boothby, V.L. Weiss, S. M. Groves, A. N. Oleskie, X. Zhang, D. Y. Maeda, J. A. Zebala, V. Quaranta…
    Citation: Molecular Cancer 2023 22:92
  35. Cancer therapy resistance is the main cause of cancer treatment failure. The mechanism of therapy resistance is a hot topic in epigenetics. As one of the most common RNA modifications, N6-methyladenosine (m6A)...

    Authors: Hengzhao Zhuang, Bo Yu, Dan Tao, Xiaoyan Xu, Yijun Xu, Jian Wang, Yang Jiao and Lili Wang
    Citation: Molecular Cancer 2023 22:91
  36. Epithelial mesenchymal transition (EMT) and mesenchymal epithelial transition (MET) are genetic determinants of cellular plasticity. These programs operate in physiological (embryonic development, wound healin...

    Authors: Azamat Akhmetkaliyev, Noura Alibrahim, Darya Shafiee and Eugene Tulchinsky
    Citation: Molecular Cancer 2023 22:90
  37. Chemoresistance is a major cause of treatment failure in colorectal cancer (CRC) therapy. In this study, the impact of the IGF2BP family of RNA-binding proteins on CRC chemoresistance was investigated using in...

    Authors: Sandra Kendzia, Susanne Franke, Tarek Kröhler, Nicole Golob-Schwarzl, Caroline Schweiger, Anna M. Toeglhofer, Christina Skofler, Stefan Uranitsch, Amin El-Heliebi, Julia Fuchs, Andreas Punschart, Philipp Stiegler, Marlen Keil, Jens Hoffmann, David Henderson, Hans Lehrach…
    Citation: Molecular Cancer 2023 22:89
  38. Neuroblastoma is the most common solid tumor in infants accounting for approximately 15% of all cancer-related deaths. Over 50% of high-risk neuroblastoma relapse, emphasizing the need of novel drug targets an...

    Authors: Sven Hagemann, Danny Misiak, Jessica L. Bell, Tommy Fuchs, Marcell I. Lederer, Nadine Bley, Monika Hämmerle, Ehab Ghazy, Wolfgang Sippl, Johannes H. Schulte and Stefan Hüttelmaier
    Citation: Molecular Cancer 2023 22:88
  39. The advent of nanotechnology has opened new possibilities for bioimaging. Metal nanoparticles (such as gold, silver, iron, copper, etc.) hold tremendous potential and offer enormous opportunities for imaging a...

    Authors: Wei Qin, Jyoti Chandra, Mohammed A.S. Abourehab, Neelima Gupta, Zhe-Sheng Chen, Prashant Kesharwani and Hui-Ling Cao
    Citation: Molecular Cancer 2023 22:87
  40. The discovery of functionally relevant KRAS effectors in lung and pancreatic ductal adenocarcinoma (LUAD and PDAC) may yield novel molecular targets or mechanisms amenable to inhibition strategies. Phospholipi...

    Authors: Rodrigo Entrialgo-Cadierno, Cristina Cueto-Ureña, Connor Welch, Iker Feliu, Irati Macaya, Laura Vera, Xabier Morales, Sandra Vietti Michelina, Pietro Scaparone, Ines Lopez, Elodie Darbo, Oihane Erice, Adrian Vallejo, Haritz Moreno, Ainhoa Goñi-Salaverri, David Lara-Astiaso…
    Citation: Molecular Cancer 2023 22:86

    The Correction to this article has been published in Molecular Cancer 2023 22:97

  41. Enhancer of zeste homolog 2 (EZH2), the key catalytic subunit of polycomb repressive complex 2 (PRC2), is overexpressed and plays an oncogenic role in various cancers through catalysis-dependent or catalysis-i...

    Authors: Jianfeng Chen, Jing Han Hong, Yulin Huang, Shini Liu, Jiaxin Yin, Peng Deng, Yichen Sun, Zhaoliang Yu, Xian Zeng, Rong Xiao, Jason Yongsheng Chan, Peiyong Guan, Yali Wang, Peili Wang, Lizhen Liu, Shijun Wen…
    Citation: Molecular Cancer 2023 22:85

Annual Journal Metrics

  • 2022 Citation Impact
    37.3 - 2-year Impact Factor
    33.1 - 5-year Impact Factor
    5.740 - SNIP (Source Normalized Impact per Paper)
    8.703 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    91 days submission to accept (Median)

    2023 Usage 
    3,569,666 downloads
    2,070 Altmetric mentions